Involuntary Groaning Induced by Levodopa Therapy in a Patient With Progressive Supranuclear Palsy
JAMA Neurol 77:1569, Park, J.E., 2020
Clinicopathologic Conference, Statin-Associated Autoimmune Myopathy
NEJM 381:275-283, Case 22-2019, 2019
Clinicopathologic Conference,Necrotizing Noninflammatory Myopathy Consistent with Exposure to Statins
NEJM 36:944-954, Case 7-2012, 2012
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Frequency, Characteristics, and Risk Factors for Amiodarone Neurotoxicity
Arch Neurol 66:865-869, Orr,C.F. &Ahlskog,E., 2009
Statin Use and the Risk of Parkinson Disease
Neurol 70:1418-1422, Wahner,A.D.,et al, 2008
Use of Antihypertensives and the Risk of Parkinson Disease
Neurol 70:1438-1444, Becker,C.,et al, 2008
What is the Risk of Developing Parkinsonism Following Neuroleptic Use?
Neurol 66:941-943, Noyes,K.,et al, 2006
Dystonia
NEJM 355:818-829, Tarsy,D. &Simon,D.K., 2006
Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease
Arch Neurol 62:1377-1381, Dodd,M.L.,et al, 2005
Underappreciated Statin-Induced Myopathic Weakness Causes Disability
Neurorehabil Neural Repair 19:259-263, Dobkin,B.H., 2005
Reversible Parkinsonism with Normal B-CIT-SPECT in Patients Exposed to Sodium Valproate
Neurol 62:1435-1437, Easterford,K.,et al, 2004
Relation Between Cholinesterase Inhibitor and Pisa Syndrome
Lancet 355:2222, Kwak,Y.T. et al, 2000
Treatment of Drug-Induced Psychosis with Quetiapine and Clozapine in Parkinson's Disease
Neurol 55:1753-1754, Dewey,R.B.Jr. & O'Suilleabhain,P.E., 2000
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
NEJM 340:757-763,801, The Parkinson Study Group, 1999
Parkinsonism after Taking Ecstasy
NEJM 340:1443, Mintzer,S.,et al, 1999
An Algorithm (Decision Tree) for the Management of Parkinson's Disease:Trtm Guidelines
Neurol 50:S1-S57, Olanow,C.W.&Koller,W.C., 1998
Early Dopaminergic Drug-Induced Hallucinations in Parkinsonian Patients
Neurol 51:811-814, Goetz,C.G.,et al, 1998
Drug-Induced Movement Disorders
Neurol Clin 16:125-139, Diederich,N.J. & Goetz,C.G., 1998
Serotonin Syndrome and the Combined Use of Deprenyl and An Antidepressant in Parkinson's Disease
Neurol 48:1070-1077, Richard,I.H.,et al, 1997
Reversible Parkinsonism and Cognitive Impairment with Chronic Valproate Use
Neurol 47:626-635, Armon,C.,et al, 1996
Clinical and Pathological Features in Hydrocarbon-Induced Parkinsonism
Ann Neurol 40:922-925, Pezzoli,G.,et al, 1996
Movement Disorders Associated with the Serotonin Selective Reuptake Inhibitors
J Clin Psychiatry 57:449-454, Leo,R.J., 1996
Neuroleptic Drug Exposure and Treatment of Parkinsonism in the Elderly:A Case-Control Study
Am J Med 99:48-54, Avorn,J.,et al, 1995
Neurotox of Antimicrob & Antimalarial Agents
In Intox of Nervous System, Part II, Handbk Clin Neurol, Elsevier Science 21 (65) :471., Moorhouse,D.F.,et al, 1995
Disabling Parkinsonism Due to Lithium: A Case Report
J Geriatr Psychiatry Neurol 8:118-119, Holroyd,S. & Smith,D., 1995
Parkinsonism Induced by Solvent Abuse
Ann NEurol 35:616-618, Uitti,R.J.,et al, 1994
Reversible Neurologic Toxicity with Fludarabine Phosphate for Mycosis Fungiodes & Chronic Lymphocytic Leukemia
Ann Int Med 118:114-116, Cohen,R.B.,et al, 1993
Drug Induced Creutzfeldt-Jakob Like Syndrome
J Psychiatr Neurosci 17:103-105, Finelli,P.F., 1992
Neuroleptic-Induced Catatonia as a Stage in the Progression Toward NMS
J Am Acad Child Adolesc Psychiatry 31:1161-1164, Woodbury,M.M.&Woodbury,M.A., 1992
Drug-Induced Movement Disorders:An Overview
In Movement Dis in Neurol & Neuropsych, Blackwell Sci Publ, Boston, 2:21., Miller,L.G.&Jankovic,J., 1992
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 47:1085-1087, Wolters,W.Ch.,et al, 1992
Extrapyramidal side Effects of Antiemetics Presenting as Psychiatric Illness
Gen Hosp Psychiatry 14:192-195, Rodgers,C., 1992
Parkinsonism and Amiodarone Therapy
Ann Neurol 25:630-632, Werner,E.G.&Olanow,C.W., 1989
Mild Parkinsonism in Persons Exposed to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)
Neurol 39:1483-1487, Tetrud,J.W.,et al, 1989
Drug-Induced Alzheimerism
Arch Neurol 45:356-357, Kurlan,R.&Como,P., 1988
Neuroleptic-Induced Parkinson's Syndrome:Clinical Features and Results of Treatment with Levodopa
JNNP 51:850-854, Hardie,R.J.&Lees,A.J., 1988
Parkinsonism, Tremor, and Depression Induced by Cinnarizine and Flunarizine
BMJ 297:722-723, Capella,D.,et al, 1988
A Creutzfeldt-Jakob Like Syndrome Due to Lithium Toxicity
JNNP 51:120-123, Smith,S.J.M.&Kocen,R.S., 1988
Extrapyramidal Disturbances Caused by Inappropriate Prescribing
BMJ 295:30-31, Pall,H.S.&Williams,A.C., 1987
Flunarizine- & -Cinnarizine-Induced Extrapyramidal Reactions
Neurol 37:881-884, Micheli,F.,et al, 1987
Bromocriptine Induced Impotence in Parkinson's Disease
BMJ 295:367-368, Cleves,L., 1987
Parkinsonism, Tardive Dyskinesia, Akathisia, & Depression Induced by Flunarizine
Lancet 1:1303-1304, Chouza,C.,et al, 1986
Frequent Neurologic Toxicity Associated with Amiodarone Therapy
Neurol 34:669-671, Charness,M.E.,et al, 1984
Drug-Induced Parkinsonism in the Elderly
Lancet 2:1082-1083, Stephen,P.J.,et al, 1984
Parkinson's Disease in a Chemist Working with l-Methyl-4-Phenyl-1, 2, 5, 6-Tetrahydropyridine
NEJM 309:310, Langston,J.W.,et al, 1983
Taste & Smell in Disease (First of Two Parts)
NEJM 308:1275-1279, Schiffman,S.S., 1983
Persisting Neurologic Sequelae of Lithium Carbonate Therapy
Arch Neurol 40:747-751, MacDonaldson,I.,et al, 1983
A Danger In Making The Diagnosis Of Parkinson's Disease
Lancet 1:1212-1213, Murdoch,P.S.,et al, 1982